ArticleInvestigational new drugs2020

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.

Andreas Johne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.